Get the Stockscreener App
2.7821
1.91%
0.0521
Heartsciences Inc stock is traded at $2.7821, with a volume of 12,390.
It is up +1.91% in the last 24 hours and down -35.90% over the past month.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
See More
Previous Close:
$2.73
Open:
$2.7609
24h Volume:
12,390
Relative Volume:
0.04
Market Cap:
$2.53M
Revenue:
-
Net Income/Loss:
$-6.39M
P/E Ratio:
-4.1524
EPS:
-0.67
Net Cash Flow:
$-6.42M
1W Performance:
-6.95%
1M Performance:
-35.90%
6M Performance:
-68.67%
1Y Performance:
-87.96%
1-Day Range:
$2.70
$2.7937
1-Week Range:
$2.70
$3.29
52-Week Range:
$2.36
$52.00
Heartsciences Inc Stock (HSCS) Company Profile
Name
Heartsciences Inc
Sector
Industry
Phone
682-237-7781
Address
550 RESERVE ST, SUITE 360, SOUTHLAKE
Heartsciences Inc Stock (HSCS) Latest News
Contrasting Heart Test Laboratories (NASDAQ:HSCS) and Bone Biologics (NASDAQ:BBLG) - Defense World
Heart Test Laboratories announces corporate name change to HeartSciences - Investing.com
Heart Test Laboratories (NASDAQ:HSCS) Stock Price Down 10.9% – Time to Sell? - Defense World
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit - ForexTV.com
Mobile Cardiac Telemetry Systems Market Players In Latest Report - WhaTech
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.34% - MSN
Heart Test Laboratories, Inc. (NASDAQ:HSCS) Short Interest Update - Defense World
A new trading data show Heart Test Laboratories Inc. (HSCS) is showing positive returns. - SETE News
Heart Test Laboratories Inc. [HSCS] is -75.15% lower this YTD. Is it still time to buy? - The DBT News
3 Penny Stocks to Watch Now, 9/25/24 - MSN
"Nasdaq Stocks Set for Explosive Growth: BNZI, SEEL, PRSO, MSS, HSCS Revamp for Big Potential" - WICZ
Heart Test Laboratories Inc. (HSCS) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Is Heart Test Laboratories Inc. (HSCS) a good investment opportunity? - US Post News
Pre-market Movers: MSS, HSCS, BIVI, GBNY, LBRDK… - RTTNews
Insider’s View: Deciphering Heart Test Laboratories Inc. (HSCS)’s Financial Health Through Ratios - The Dwinnex
Heart Test Laboratories’ (HSCS) Buy Rating Reaffirmed at Ascendiant Capital Markets - Defense World
Heart Test Laboratories, Inc. (NASDAQ:HSCS) Short Interest Down 11.8% in August - Defense World
Heart Test (HSCS) Stock Gains After-Market Following Volatile Trading - Stocks Telegraph
Shares of HeartSciences get a bump from announcement of non-dilutive financing - Kursiv Media
Closing Bell Recap: Heart Test Laboratories Inc. (HSCS) Ends at 2.79, Reflecting a -1.06 Downturn - The Dwinnex
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results - ForexTV.com
How analysts predict Heart Test Laboratories Inc. (HSCS) will perform this quarter? - US Post News
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission - StockTitan
Heart Test Laboratories (NASDAQ:HSCS) Shares Down 13% - Defense World
HSCS stock touches 52-week low at $3.01 amid sharp annual decline - Investing.com Australia
Heart Test Laboratories, Inc. announced that it expects to receive $2.01 million in funding - Marketscreener.com
Heart Test Labs extends loan maturity to 2025 - Investing.com
Heart Test Laboratories (NASDAQ:HSCS) Stock Price Up 9.2% - Defense World
Heart Test Labs stock target cut by two thirds, maintains buy - Investing.com
HSCSHeart Test Laboratories, Inc. Latest Stock News & Market Updates - StockTitan
HeartSciences reports fiscal 2024 financial results - Medical Buyer
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results - ForexTV.com
Heart Test announces MyoVista wavECG selected by Innovation Value Institute - TipRanks
Innovation Value Institute Analysis Demonstrates - GlobeNewswire
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency - StockTitan
Heart Test Laboratories announces analysis on MyoVista wavECG potential - TipRanks
Heart Test Laboratories (NASDAQ:HSCS) Trading Down 1.8% - Defense World
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare - GlobeNewswire
HeartSciences to Present at the LD Micro Invitational XIV Conference - WICZ
HeartSciences Adds Another International Patent To Its IP Portfolio - MPO-mag
Doctors Say Providence’s Sale of Its Hospitals’ Testing Labs Has Endangered Patients - Willamette Week
In the Green: Heart Test Laboratories Inc. (HSCS) Closes at 4.04, Up/Down -8.60 from Previous Day - The Dwinnex
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction - BioSpace
- Invest Chronicle - The InvestChronicle
HeartSciences Announces Allowance of U.S Patent for AI-ECG - GlobeNewswire
Heart Test Laboratories (NASDAQ:HSCS) Trading Down 8.8% - Defense World
Dallas, Texas publicly-traded companies: 2024 stock prices | wfaa.com - WFAA.com
Which DFW companies have performed best, worst on stock markets in 2024? - WFAA.com
(HSCS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cardiovascular Diagnostic Testing Market's Expected Expansion to $15,430.46 Million by 2030, Demonstrating an - EIN News
Anumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology ... - Diagnostic and Interventional Cardiology
Heartsciences Inc Stock (HSCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):